Zasocitinib — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

7 Recruiting

4 Completed trials

1 Sponsors

19 Countries

Phase III

Phase II

Phase III: 8 Phase II: 5

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Psoriatic arthropathy 3 Colitis ulcerative 2 Psoriasis 1 Crohn´s disease 1 Crohn's disease 1 Vitiligo 1

Sponsors using this IMP

Takeda Development Center Americas Inc. 13

All trials

13 total

A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Phase III 13 countries Takeda Development Center Americas Inc.
A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending

2025-522831-33-00 Phase II 4 countries Takeda Development Center Americas Inc.
Zasocitinib in Nonsegmental Vitiligo Recruiting

2025-522309-40-00 Phase II 4 countries Takeda Development Center Americas Inc.
A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less… Recruiting

2025-522567-15-00 Phase III 4 countries Takeda Development Center Americas Inc.
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Phase II 14 countries Takeda Development Center Americas Inc.
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Phase III 12 countries Takeda Development Center Americas Inc.
A Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior… Recruiting

2024-513112-99-00 Phase III 4 countries Takeda Development Center Americas Inc.
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Phase III 9 countries Takeda Development Center Americas Inc.
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Phase II 14 countries Takeda Development Center Americas Inc.
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Phase II 13 countries Takeda Development Center Americas Inc.
A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate-… Ended

2024-512497-10-00 Phase III 5 countries Takeda Development Center Americas Inc.
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Phase III 9 countries Takeda Development Center Americas Inc.
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended

2023-505841-22-00 Phase III 3 countries Takeda Development Center Americas Inc.

Showing 1–13 of 13 trials

← All drugs A–Z